These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37310917)

  • 1. Impact of guselkumab on three cases of SSc accompanying psoriasis.
    Fukasawa T; Yoshizaki-Ogawa A; Yoshizaki A; Sato S
    Rheumatology (Oxford); 2024 Jan; 63(1):e6-e8. PubMed ID: 37310917
    [No Abstract]   [Full Text] [Related]  

  • 2. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison.
    Ruggiero A; Fabbrocini G; Cinelli E; Megna M
    J Am Acad Dermatol; 2021 Oct; 85(4):1028-1030. PubMed ID: 33762130
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review.
    Welsh E; Cardenas-de la Garza JA; García-Lozano JA; Flores-Gutierrez DP
    An Bras Dermatol; 2024; 99(2):319-320. PubMed ID: 38065780
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab.
    Megna M; Marano L; Camela E; Potestio L; Fabbrocini G; Scalvenzi M; Guerrasio G
    Dermatol Ther; 2022 Oct; 35(10):e15766. PubMed ID: 35959513
    [No Abstract]   [Full Text] [Related]  

  • 5. Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trial.
    Rousel J; Bergmans ME; van der Meulen LWJ; Pagan L; de Bruin DT; de Kam ML; Klarenbeek NB; Bouwstra JA; Seyger MMB; van den Reek JMPA; Niemeyer-van der Kolk T; Rissmann R; van Doorn MBA;
    J Am Acad Dermatol; 2024 Feb; 90(2):395-397. PubMed ID: 37804933
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study.
    Ruiz-Villaverde R; Galan-Gutierrez M; Armario-Hita JC; Rodriguez-Fernandez-Freire L
    Actas Dermosifiliogr; 2024 Mar; 115(3):321-323. PubMed ID: 37923077
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on: 'Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab'.
    Akturk S; Altunisik N; Buyukavci R; Turkmen D
    Clin Exp Dermatol; 2022 Jul; 47(7):1363-1364. PubMed ID: 35266569
    [No Abstract]   [Full Text] [Related]  

  • 8. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study: An analysis with considerations for future studies.
    Javaid K; Andruszka C
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):e302-e303. PubMed ID: 37907280
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety profile of guselkumab in treatment of patients with psoriasis and coexisting hepatitis B or C: A multicenter prospective cohort study.
    Huang YH; Yen JS; Li SH; Chiu HY
    J Am Acad Dermatol; 2024 May; 90(5):1083-1086. PubMed ID: 38307145
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
    Blauvelt A; Thaçi D; Papp KA; Ho V; Ghoreschi K; Kim BS; Miller M; Shen YK; You Y; Chan D; Yu J; Yang YW; Lebwohl MG; Gottlieb AB; Crowley J; Foley P
    Br J Dermatol; 2023 Jul; 189(1):132-134. PubMed ID: 36944555
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2.
    Armstrong A; Eyerich K; Conrad C; Zhu Y; Yang YW; Miller M; You Y; Shen YK; Foley P; Griffiths CEM; Strober B
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1375-e1379. PubMed ID: 37415560
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis.
    Van Muijen ME; Thomas SE; Vellinga D; Bouwman S; Van Doorn MBA; Politiek K; Otero ME; Van den Reek JMPA; De Jong EMGJ
    Acta Derm Venereol; 2022 Aug; 102():adv00755. PubMed ID: 35788690
    [No Abstract]   [Full Text] [Related]  

  • 13. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
    Ferris LK; Ott E; Jiang J; Hong HC; Li S; Han C; Baran W
    J Dermatolog Treat; 2020 Mar; 31(2):152-159. PubMed ID: 30887876
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-life experience of guselkumab in patients with psoriasis.
    Snast I; Sherman S; Holzman R; Hodak E; Pavlovsky L
    Dermatol Ther; 2020 Nov; 33(6):e13964. PubMed ID: 32618384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Treatment With Secukinumab With Exacerbation of Dermatomyositis in a Patient With Psoriasis.
    Perna DL; Callen JP; Schadt CR
    JAMA Dermatol; 2022 Apr; 158(4):454-456. PubMed ID: 35171205
    [No Abstract]   [Full Text] [Related]  

  • 17. Guselkumab vs. secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal.
    Wan MT; Takeshita J
    Br J Dermatol; 2021 Feb; 184(2):259-260. PubMed ID: 32407562
    [No Abstract]   [Full Text] [Related]  

  • 18. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
    Eyerich K; Weisenseel P; Pinter A; Schäkel K; Asadullah K; Wegner S; Muñoz-Elias EJ; Bartz H; Taut FJH; Reich K
    BMJ Open; 2021 Sep; 11(9):e049822. PubMed ID: 34518264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis.
    Cao Z; Liu Z; Zhu X; Yang Q; Xu Q; Zhang C
    Ren Fail; 2022 Dec; 44(1):826-830. PubMed ID: 35546261
    [No Abstract]   [Full Text] [Related]  

  • 20. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
    Gordon KB; Armstrong AW; Han C; Foley P; Song M; Wasfi Y; You Y; Shen YK; Reich K
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.